Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2006

01-05-2006 | Phase I Studies

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

Authors: Athanassios Argiris, Victoria Kut, Lynn Luong, Michael J. Avram

Published in: Investigational New Drugs | Issue 3/2006

Login to get access
Metadata
Title
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer
Authors
Athanassios Argiris
Victoria Kut
Lynn Luong
Michael J. Avram
Publication date
01-05-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-3259-4

Other articles of this Issue 3/2006

Investigational New Drugs 3/2006 Go to the issue

Phase II Studies

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

Preclinical Studies

Suppression of primary breast, colon, gastric and bladder cancers cell growth in vitro by CKBM, a natural product

Preclinical Studies

Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial

Phase I Studies

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

Phase I Studies

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

Phase I Studies

Phase I trial of oral talactoferrin alfa in refractory solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits